From science to clinical practice – lessons from REWIND


Dulaglutide is the first and only GLP-1 RA to demonstrate both primary and secondary CVD prevention in diabetes patients

You will learn:
• The burden of cardiovascular risk across the disease continuum of type 2 diabetes mellitus (T2DM)
• The importance of early primary and secondary prevention strategies beyond glycaemic control to provide protection against the development of cardiovascular disease (CVD) in the patient with T2DM
• The cardiovascular effects of the pharmacological management of hyperglycaemia, and the role of GLP-1 RA therapy along the continuum of T2DM disease progression.

To access this module, please register or login: